Header Logo

Connection

DONALD PARSONS to Child

Back to Details
This is a "connection" page, showing publications DONALD PARSONS has written about Child.
DONALD PARSONS
Connection Strength
1.012
Child
  1. Phase II Study of Samotolisib in Children and Young Adults With Tumors Harboring Phosphoinositide 3-Kinase/Mammalian Target of Rapamycin Pathway Alterations: Pediatric MATCH APEC1621D. JCO Precis Oncol. 2024 Sep; 8:e2400258.
    View in: PubMed
    Score: 0.057
  2. Phase II study of vemurafenib in children and young adults with tumors harboring BRAF V600 mutations: NCI-COG pediatric MATCH trial (APEC1621) Arm G. Oncologist. 2024 Aug 05; 29(8):723-e1093.
    View in: PubMed
    Score: 0.056
  3. Recent Advancements and Innovations in Pediatric Precision Oncology. J Pediatr Hematol Oncol. 2024 07 01; 46(5):262-271.
    View in: PubMed
    Score: 0.056
  4. Phase II Study of Ulixertinib in Children and Young Adults With Tumors Harboring Activating Mitogen-Activated Protein Kinase Pathway Alterations: APEC1621J of the National Cancer Institute-Children's Oncology Group Pediatric MATCH Trial. JCO Precis Oncol. 2024 Jun; 8:e2400103.
    View in: PubMed
    Score: 0.056
  5. Circulating tumor DNA sequencing of pediatric solid and brain tumor patients: An institutional feasibility study. Pediatr Hematol Oncol. 2023; 40(8):719-738.
    View in: PubMed
    Score: 0.052
  6. TRK inhibition for pediatric and adult central nervous system tumors: Early promise and future questions. Neuro Oncol. 2022 06 01; 24(6):1008-1009.
    View in: PubMed
    Score: 0.048
  7. Phase II Study of Selumetinib in Children and Young Adults With Tumors Harboring Activating Mitogen-Activated Protein Kinase Pathway Genetic Alterations: Arm E of the NCI-COG Pediatric MATCH Trial. J Clin Oncol. 2022 07 10; 40(20):2235-2245.
    View in: PubMed
    Score: 0.048
  8. Actionable Tumor Alterations and Treatment Protocol Enrollment of Pediatric and Young Adult Patients With Refractory Cancers in the National Cancer Institute-Children's Oncology Group Pediatric MATCH Trial. J Clin Oncol. 2022 07 10; 40(20):2224-2234.
    View in: PubMed
    Score: 0.048
  9. Genomic analysis and preclinical xenograft model development identify potential therapeutic targets for MYOD1-mutant soft-tissue sarcoma of childhood. J Pathol. 2021 09; 255(1):52-61.
    View in: PubMed
    Score: 0.045
  10. Integrated DNA and RNA sequencing reveals targetable alterations in metastatic pediatric papillary thyroid carcinoma. Pediatr Blood Cancer. 2021 01; 68(1):e28741.
    View in: PubMed
    Score: 0.043
  11. Activating MAPK1 (ERK2) mutation in an aggressive case of disseminated juvenile xanthogranuloma. Oncotarget. 2017 Jul 11; 8(28):46065-46070.
    View in: PubMed
    Score: 0.034
  12. Renal cell carcinoma harboring somatic TSC2 mutations in a child with methylmalonic acidemia. Pediatr Blood Cancer. 2017 05; 64(5).
    View in: PubMed
    Score: 0.033
  13. Applications of Genomic Sequencing in Pediatric CNS Tumors. Oncology (Williston Park). 2016 May; 30(5):411-23.
    View in: PubMed
    Score: 0.032
  14. The genetic landscape of the childhood cancer medulloblastoma. Science. 2011 Jan 28; 331(6016):435-9.
    View in: PubMed
    Score: 0.022
  15. Anaplastic meningioma in a 6-year-old with somatic YAP1::MAML2 fusion and multiple endocrine neoplasia type 4 (MEN4) syndrome. Cancer Genet. 2025 Apr; 292-293:106-110.
    View in: PubMed
    Score: 0.015
  16. Clinical Characteristics and Outcomes of Central Nervous System Tumors Harboring NTRK Gene Fusions. Clin Cancer Res. 2025 Feb 03; 31(3):561-572.
    View in: PubMed
    Score: 0.015
  17. Comparing the Diagnostic Yield of Germline Exome Versus Panel Sequencing in the Diverse Population of the Texas KidsCanSeq Pediatric Cancer Study. JCO Precis Oncol. 2024 Sep; 8:e2400187.
    View in: PubMed
    Score: 0.014
  18. Olaparib for childhood tumors harboring defects in DNA damage repair genes: arm H of the NCI-COG Pediatric MATCH trial. Oncologist. 2024 Jul 05; 29(7):638-e952.
    View in: PubMed
    Score: 0.014
  19. Paediatric strategy forum for medicinal product development of PI3-K, mTOR, AKT and GSK3? inhibitors in children and adolescents with cancer. Eur J Cancer. 2024 Aug; 207:114145.
    View in: PubMed
    Score: 0.014
  20. Phase I Trial of GD2.CART Cells Augmented With Constitutive Interleukin-7 Receptor for Treatment of High-Grade Pediatric CNS Tumors. J Clin Oncol. 2024 Aug 10; 42(23):2769-2779.
    View in: PubMed
    Score: 0.014
  21. Families' experiences accessing care after genomic sequencing in the pediatric cancer context: "It's just been a big juggle". J Genet Couns. 2024 Dec; 33(6):1337-1350.
    View in: PubMed
    Score: 0.014
  22. Tazemetostat for tumors harboring SMARCB1/SMARCA4 or EZH2 alterations: results from NCI-COG pediatric MATCH APEC1621C. J Natl Cancer Inst. 2023 11 08; 115(11):1355-1363.
    View in: PubMed
    Score: 0.013
  23. Children's Oncology Group's 2023 blueprint for research: Developmental therapeutics. Pediatr Blood Cancer. 2023 09; 70 Suppl 6:e30563.
    View in: PubMed
    Score: 0.013
  24. Epigenetic Alterations of Repeated Relapses in Patient-matched Childhood Ependymomas. Nat Commun. 2022 11 05; 13(1):6689.
    View in: PubMed
    Score: 0.012
  25. The children's brain tumor network (CBTN) - Accelerating research in pediatric central nervous system tumors through collaboration and open science. Neoplasia. 2023 01; 35:100846.
    View in: PubMed
    Score: 0.012
  26. Clinical and molecular features of pediatric cancer patients with Lynch syndrome. Pediatr Blood Cancer. 2022 11; 69(11):e29859.
    View in: PubMed
    Score: 0.012
  27. A Validation Framework for Somatic Copy Number Detection in Targeted Sequencing Panels. J Mol Diagn. 2022 07; 24(7):760-774.
    View in: PubMed
    Score: 0.012
  28. Durable Response to Larotrectinib in a Child With Histologic Diagnosis of Recurrent Disseminated Ependymoma Discovered to Harbor an NTRK2 Fusion: The Impact of Integrated Genomic Profiling. JCO Precis Oncol. 2021; 5.
    View in: PubMed
    Score: 0.011
  29. Phase II study of peginterferon alpha-2b for patients with unresectable or recurrent craniopharyngiomas: a Pediatric Brain Tumor Consortium report. Neuro Oncol. 2020 11 26; 22(11):1696-1704.
    View in: PubMed
    Score: 0.011
  30. Reliable tumor detection by whole-genome methylation sequencing of cell-free DNA in cerebrospinal fluid of pediatric medulloblastoma. Sci Adv. 2020 10; 6(42).
    View in: PubMed
    Score: 0.011
  31. Fixing the leaky pipeline: identifying solutions for improving pediatrician-scientist training during pediatric residency. Pediatr Res. 2020 08; 88(2):163-167.
    View in: PubMed
    Score: 0.010
  32. Precision Medicine in Pediatric Oncology. Surg Oncol Clin N Am. 2020 01; 29(1):63-72.
    View in: PubMed
    Score: 0.010
  33. Molecular profiling and targeted therapy in pediatric gliomas: review and consensus recommendations. Neuro Oncol. 2019 08 05; 21(8):968-980.
    View in: PubMed
    Score: 0.010
  34. Characterization of pediatric hepatocellular carcinoma reveals genomic heterogeneity and diverse signaling pathway activation. Pediatr Blood Cancer. 2019 07; 66(7):e27745.
    View in: PubMed
    Score: 0.010
  35. Exome sequencing disclosures in pediatric cancer care: Patterns of communication among oncologists, genetic counselors, and parents. Patient Educ Couns. 2019 04; 102(4):680-686.
    View in: PubMed
    Score: 0.009
  36. Undifferentiated Sarcomas in Children Harbor Clinically Relevant Oncogenic Fusions and Gene Copy-Number Alterations: A Report from the Children's Oncology Group. Clin Cancer Res. 2018 08 15; 24(16):3888-3897.
    View in: PubMed
    Score: 0.009
  37. CNS Langerhans cell histiocytosis: Common hematopoietic origin for LCH-associated neurodegeneration and mass lesions. Cancer. 2018 06 15; 124(12):2607-2620.
    View in: PubMed
    Score: 0.009
  38. Portero versus portador: Spanish interpretation of genomic terminology during whole exome sequencing results disclosure. Per Med. 2017 11; 14(6):503-514.
    View in: PubMed
    Score: 0.009
  39. Haploinsufficiency of the Chromatin Remodeler BPTF Causes Syndromic Developmental and Speech Delay, Postnatal Microcephaly, and Dysmorphic Features. Am J Hum Genet. 2017 Oct 05; 101(4):503-515.
    View in: PubMed
    Score: 0.009
  40. Target and Agent Prioritization for the Children's Oncology Group-National Cancer Institute Pediatric MATCH Trial. J Natl Cancer Inst. 2017 05 01; 109(5).
    View in: PubMed
    Score: 0.009
  41. Pediatric oncology enters an era of precision medicine. Curr Probl Cancer. 2017 May - Jun; 41(3):194-200.
    View in: PubMed
    Score: 0.008
  42. 50 Years Ago in The Journal of Pediatrics: Adrenocortical Neoplasms with Hemihypertrophy, Brain Tumors, and Other Disorders. J Pediatr. 2017 01; 180:115.
    View in: PubMed
    Score: 0.008
  43. Alternative genetic mechanisms of BRAF activation in Langerhans cell histiocytosis. Blood. 2016 11 24; 128(21):2533-2537.
    View in: PubMed
    Score: 0.008
  44. Clinical Sequencing Exploratory Research Consortium: Accelerating Evidence-Based Practice of Genomic Medicine. Am J Hum Genet. 2016 06 02; 98(6):1051-1066.
    View in: PubMed
    Score: 0.008
  45. Novel patient-derived xenograft and cell line models for therapeutic testing of pediatric liver cancer. J Hepatol. 2016 08; 65(2):325-33.
    View in: PubMed
    Score: 0.008
  46. Is Whole-Exome Sequencing an Ethically Disruptive Technology? Perspectives of Pediatric Oncologists and Parents of Pediatric Patients With Solid Tumors. Pediatr Blood Cancer. 2016 Mar; 63(3):511-5.
    View in: PubMed
    Score: 0.008
  47. When Participants in Genomic Research Grow Up: Contact and Consent at the Age of Majority. J Pediatr. 2016 Jan; 168:226-231.e1.
    View in: PubMed
    Score: 0.008
  48. Pediatric Cancer Genetics Research and an Evolving Preventive Ethics Approach for Return of Results after Death of the Subject. J Law Med Ethics. 2015; 43(3):529-37.
    View in: PubMed
    Score: 0.007
  49. BCOR-CCNB3 fusions are frequent in undifferentiated sarcomas of male children. Mod Pathol. 2015 Apr; 28(4):575-86.
    View in: PubMed
    Score: 0.007
  50. Mutations of PTCH1, MLL2, and MLL3 are not frequent events in hepatoblastoma. Pediatr Blood Cancer. 2012 Jun; 58(6):1006-7.
    View in: PubMed
    Score: 0.006
  51. Survey of the indications for use of emergency tourniquets. J Spec Oper Med. 2011; 11(1):30-34.
    View in: PubMed
    Score: 0.005
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.